<DOC>
	<DOCNO>NCT00588536</DOCNO>
	<brief_summary>The objective study determine incidence complete partial response duration response patient Langerhans Cell Histiocytosis ( LCH ) treat sequential administration oral 6-Thioguanine ( 6-TG ) Methotrexate ( MTX ) .</brief_summary>
	<brief_title>Study Sequential Administration Oral 6-Thioguanine After Methotrexate Patients With LCH</brief_title>
	<detailed_description />
	<mesh_term>Histiocytosis</mesh_term>
	<mesh_term>Histiocytosis , Langerhans-Cell</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Patients histologic proof LCH multifocal multisystem disease involvement . Patients must life expectancy least 8 week . All patient must ECOG performance level rating &lt; 2 . Patients parent ( guardian ) must sign informed consent indicate aware investigational nature study , use commercially available drug . Patients must recover toxic effect prior therapy enter study least 2 week elapse since end last course chemotherapy . Patients must adequate liver function ( bilirubin _ &lt; 2.0 mg/dl , SGOT le 1.5 time normal ( unless due disease ) , adequate renal function ( creatinine &lt; _ 1.5 mg/dl , creatinine clearance &gt; _ 60 ml/min/1.73 m2 ) normal electrolyte . Patients granulocyte count &gt; 500/uL platelet count &gt; _ 100,000/uL ( unless due disease involvement bone marrow ) . Male female patient childbearing age use effective method contraception , sexually active . Patients active infection significant medical condition disease ( LCH ) shall exclude .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Langerhans Cell Histiocytosis</keyword>
	<keyword>LCH</keyword>
	<keyword>6-Thioguanine</keyword>
	<keyword>6-TG</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>MTX</keyword>
	<keyword>94-132</keyword>
</DOC>